Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance

Background: Omalizumab is approved as add-on therapy for pediatric asthma since 2013 in Japan, however, its data in clinical practice is limited. This post-marketing surveillance aimed to evaluate long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic as...

Full description

Bibliographic Details
Main Authors: Noriko Nakamura, Yuka Kashitani, Hajime Yoshisue, Makoto Nagasaki, Takayoshi Sasajima
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Allergology International
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893021000010